Usefulness of combined renin-angiotensin system inhibitors and diuretic treatment in patients hospitalized with COVID-19

The American Journal of CardiologyPalazzuoli A, Tecson KM, Vicenzi M, et al. | January 12, 2022


Indicated patients show limitation of clinical deterioration and prevention of cardiovascular/thrombotic complications of COVID-19 in correlation with antecedent use of renin-angiotensin system inhibitors (RASi). Researchers aimed at determining the differential effect of RASi continuation in patients hospitalized with COVID-19 according to diuretic use.

  • Using the Coracle registry, 286 patients are analyzed herein; 100 patients (35.0%) continued RASi and 186 (65%) discontinued.

  • A total of 98 patients were receiving treatment with a diuretic; 51 (52%) of those continued RASi.

  • After accounting for age, cardiovascular disease, and laboratory values, a decrease in the risk of mortality was recorded by approximately 77% for patients treated with diuretics in correlation with continuing RASi, but there was no alteration in the risk in patients treated with RASi alone.

  • Overall there was a reduced in-hospital mortality in correlation with continuing RASi in patients concomitantly treated with diuretics.

Read the full article on The American Journal of Cardiology